Drugs / Rejuvesol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02485366 | Jun 2020 → Jun 2021 | congenital heart disease | Duke University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02731157 | Dec 2016 → Dec 2017 | sickle cell disease | Duke University | Completed | Missed primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rejuvesol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02485366 ↗ |